Johnson & Johnson - Public Comps and Valuation Multiples

Johnson & Johnson Overview

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Founded

1887

HQ

Employees

138.1K+

Website

jnj.com

Sectors

Biopharmaceuticals
Medical Devices
Drug Development & Therapeutics
BioTech
DeepTech
HealthTech

Financials

LTM Revenue $92.9B

LTM EBITDA $35.0B

EV

$483B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Johnson & Johnson Financials

As of October 2025, Johnson & Johnson reported last 12-month revenue of $92.9B and EBITDA of $35.0B.

In the same period, Johnson & Johnson generated $66.8B in LTM gross profit and $26.0B in net income.

See Johnson & Johnson valuation multiples based on analyst estimates

Johnson & Johnson P&L

In the most recent fiscal year, Johnson & Johnson reported revenue of $88.8B and EBITDA of $24.8B.

Johnson & Johnson expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Johnson & Johnson valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$92.9B	XXX	$88.8B	XXX	XXX	XXX
Gross Profit	$66.8B	XXX	$61.4B	XXX	XXX	XXX
Gross Margin	72%	XXX	69%	XXX	XXX	XXX
EBITDA	$35.0B	XXX	$24.8B	XXX	XXX	XXX
EBITDA Margin	38%	XXX	28%	XXX	XXX	XXX
EBIT	$30.1B	XXX	$22.1B	XXX	XXX	XXX
EBIT Margin	32%	XXX	25%	XXX	XXX	XXX
Net Profit	$26.0B	XXX	$14.1B	XXX	XXX	XXX
Net Margin	28%	XXX	16%	XXX	XXX	XXX
Net Debt	XXX	XXX	$12.5B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Johnson & Johnson including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $92.9B. EBITDA for the last twelve months was $35.0B. In the most recent fiscal year, Johnson & Johnson achieved $88.8B in revenue and $24.8B in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$92.9B	Analyst estimates available to subscribers	$88.8B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$66.8B	Analyst estimates available to subscribers	$61.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	71.9% gross margin	Analyst estimates available to subscribers	69.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$35.0B	Analyst estimates available to subscribers	$24.8B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	37.7% EBITDA margin	Analyst estimates available to subscribers	27.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$30.1B	Analyst estimates available to subscribers	$22.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	32.4% EBIT margin	Analyst estimates available to subscribers	24.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$26.0B	Analyst estimates available to subscribers	$14.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	28.0% net profit margin	Analyst estimates available to subscribers	15.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$12.5B	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Johnson & Johnson

This financial data table provides comprehensive performance metrics for Johnson & Johnson, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Johnson & Johnson generated $92.9B in revenue over the last twelve months.
The company achieved $35.0B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $66.8B.
Net income over the last twelve months reached $26.0B.

Fiscal Year Performance

In the most recent fiscal year, Johnson & Johnson reported $88.8B in total revenue.
Fiscal year EBITDA was $24.8B.
The company maintained a gross profit margin of 69.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 27.9%.
Net profit margin reached 15.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Johnson & Johnson. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Johnson & Johnson Stock Performance

Johnson & Johnson has current market cap of $455B, and EV of $483B.

Market Cap Evolution

Johnson & Johnson Stock Data

As of October 31, 2025, Johnson & Johnson's stock price is $189.

See Johnson & Johnson trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$483B	$455B	XXX	XXX	XXX	XXX	$10.72

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Johnson & Johnson Valuation Multiples

Johnson & Johnson's trades at 5.4x EV/Revenue multiple, and 19.5x EV/EBITDA.

See valuation multiples for Johnson & Johnson and 15K+ public comps

Johnson & Johnson Financial Valuation Multiples

As of October 31, 2025, Johnson & Johnson has market cap of $455B and EV of $483B.

Equity research analysts estimate Johnson & Johnson's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Johnson & Johnson has a P/E ratio of 17.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$455B	XXX	$455B	XXX	XXX	XXX
EV (current)	$483B	XXX	$483B	XXX	XXX	XXX
EV/Revenue	5.2x	XXX	5.4x	XXX	XXX	XXX
EV/EBITDA	13.8x	XXX	19.5x	XXX	XXX	XXX
EV/EBIT	16.0x	XXX	21.8x	XXX	XXX	XXX
EV/Gross Profit	7.2x	XXX	n/a	XXX	XXX	XXX
P/E	17.5x	XXX	32.4x	XXX	XXX	XXX
EV/FCF	22.8x	XXX	26.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Johnson & Johnson Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Johnson & Johnson Margins & Growth Rates

Johnson & Johnson's last 12 month revenue growth is 5%

Johnson & Johnson's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.

Johnson & Johnson's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Johnson & Johnson's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Johnson & Johnson and other 15K+ public comps

Johnson & Johnson Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	5%	XXX	5%	XXX	XXX	XXX
EBITDA Margin	38%	XXX	28%	XXX	XXX	XXX
EBITDA Growth	6%	XXX	24%	XXX	XXX	XXX
Rule of 40	33%	XXX	33%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	51%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.6M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	19%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	44%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial